Buy or sell Samumed stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Samumed Stock

Medical Research & Development



Notable Investors

Starling group


San Diego CA, US

Total Funding


About Samumed Stock

Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.


Polar Light Ventures


Starling group


Vickers Venture Partners


Funding History

September 2013$220M
August 2018$438M


Chief Executive Officer

Osman Kibar

Chief Medical Officer

Yusuf Yazici

Chief Information Officer

Blake Mobley

Chief Scientific Officer

Michael White


Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Samumed or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 260K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: